TY - JOUR
T1 - Pre-Procedural Glucose Levels and the Risk for Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography
AU - Stolker, Joshua M.
AU - McCullough, Peter A.
AU - Rao, Seshu
AU - Inzucchi, Silvio E.
AU - Spertus, John A.
AU - Maddox, Thomas M.
AU - Masoudi, Frederick A.
AU - Xiao, Lan
AU - Kosiborod, Mikhail
N1 - Funding Information:
The research for this analysis was supported by the American Heart Association Career Development Award in Implementation Research, awarded to Dr. Kosiborod. Dr. Stolker has received speaking honoraria from AstraZeneca Pharmaceuticals and Pfizer Pharmaceuticals; has served as a consultant to Novo Nordisk; and has served on the advisory board of Educational Testing Consultants, LLC. Dr. Inzucchi has received research grant support from Eli Lilly . Dr. Spertus has received research grant support from Sanofi-Aventis and Eli Lilly . Dr. Masoudi was previously a member of the advisory board of Takeda Pharmaceuticals. Dr. Kosiborod has served on the advisory board of Sanofi-Aventis and has received speaking honoraria from the Vascular Biology Working Group and DiaVed, Inc. The Cerner Corporation collected deidentified clinical information for the Health Facts database. The Cerner Corporation had no role in study design, data analysis, interpretation of findings, or writing of the manuscript. The American Heart Association had no role in the study.
PY - 2010/4/6
Y1 - 2010/4/6
N2 - Objectives: We sought to evaluate whether pre-procedural glucose levels are associated with contrast-induced acute kidney injury (CI-AKI) after coronary angiography. Background: Although diabetes is a known risk factor for CI-AKI in patients undergoing coronary angiography, whether elevated pre-procedural glucose levels (regardless of pre-existing diabetes) are associated with higher risk for CI-AKI is unknown. Methods: We evaluated 6,358 patients with acute myocardial infarctions undergoing coronary angiography. Patients were stratified into 5 pre-procedural glucose groups: <110 mg/dl, 110 to <140 mg/dl, 140 to <170 mg/dl, 170 to <200 mg/dl, and ≥200 mg/dl. Logistic regression models were used to evaluate the relationship between glucose levels and risk for CI-AKI, first in the entire cohort and then in patients with and without established diabetes. The primary outcome was CI-AKI (≥0.3 mg/dl absolute or ≥50% relative serum creatinine increase during 48 h after the procedure). Results: The relationship between pre-procedural glucose and CI-AKI varied markedly in patients with and without diabetes. There was a strong association between glucose and CI-AKI risk in patients without diabetes (CI-AKI rates across the 5 glucose groups from lowest to highest: 8.2%, 9.9%, 12.4%, 14.9%, and 24.3%; p < 0.001), but not in patients with diabetes (20.9%, 16.1%, 16.3%, 14.8%, and 19.2%, respectively; p = 0.24; p for glucose × diabetes interaction <0.001). After adjusting for confounders (including baseline glomerular filtration rate), the relationship between higher glucose and greater CI-AKI risk persisted in patients without diabetes (odds ratios [95% confidence intervals] for glucose groups of 110 to <140 mg/dl, 140 to <170, mg/dl 170 to <200 mg/dl, and ≥200 mg/dl: 1.31 [1.00 to 1.71], 1.51 [1.11 to 2.10], 1.58 [1.03 to 2.43], and 2.14 [1.46 to 3.14] vs. glucose <110 mg/dl, respectively), but this relationship was not seen in patients with established diabetes. Conclusions: Elevated pre-procedural glucose is associated with greater risk for CI-AKI in patients without known diabetes who undergo coronary angiography in the setting of acute myocardial infarction. Measures used to prevent CI-AKI should be considered in these patients.
AB - Objectives: We sought to evaluate whether pre-procedural glucose levels are associated with contrast-induced acute kidney injury (CI-AKI) after coronary angiography. Background: Although diabetes is a known risk factor for CI-AKI in patients undergoing coronary angiography, whether elevated pre-procedural glucose levels (regardless of pre-existing diabetes) are associated with higher risk for CI-AKI is unknown. Methods: We evaluated 6,358 patients with acute myocardial infarctions undergoing coronary angiography. Patients were stratified into 5 pre-procedural glucose groups: <110 mg/dl, 110 to <140 mg/dl, 140 to <170 mg/dl, 170 to <200 mg/dl, and ≥200 mg/dl. Logistic regression models were used to evaluate the relationship between glucose levels and risk for CI-AKI, first in the entire cohort and then in patients with and without established diabetes. The primary outcome was CI-AKI (≥0.3 mg/dl absolute or ≥50% relative serum creatinine increase during 48 h after the procedure). Results: The relationship between pre-procedural glucose and CI-AKI varied markedly in patients with and without diabetes. There was a strong association between glucose and CI-AKI risk in patients without diabetes (CI-AKI rates across the 5 glucose groups from lowest to highest: 8.2%, 9.9%, 12.4%, 14.9%, and 24.3%; p < 0.001), but not in patients with diabetes (20.9%, 16.1%, 16.3%, 14.8%, and 19.2%, respectively; p = 0.24; p for glucose × diabetes interaction <0.001). After adjusting for confounders (including baseline glomerular filtration rate), the relationship between higher glucose and greater CI-AKI risk persisted in patients without diabetes (odds ratios [95% confidence intervals] for glucose groups of 110 to <140 mg/dl, 140 to <170, mg/dl 170 to <200 mg/dl, and ≥200 mg/dl: 1.31 [1.00 to 1.71], 1.51 [1.11 to 2.10], 1.58 [1.03 to 2.43], and 2.14 [1.46 to 3.14] vs. glucose <110 mg/dl, respectively), but this relationship was not seen in patients with established diabetes. Conclusions: Elevated pre-procedural glucose is associated with greater risk for CI-AKI in patients without known diabetes who undergo coronary angiography in the setting of acute myocardial infarction. Measures used to prevent CI-AKI should be considered in these patients.
KW - acute kidney injury
KW - contrast nephropathy
KW - coronary angiography
KW - diabetes
KW - glucose
KW - myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=77949908191&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2009.09.072
DO - 10.1016/j.jacc.2009.09.072
M3 - Article
C2 - 20359592
AN - SCOPUS:77949908191
SN - 0735-1097
VL - 55
SP - 1433
EP - 1440
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 14
ER -